Bicara Therapeutics (BCAX) Assets Average (2024 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Assets Average of $492.3 million for Q1 2026, little changed year-over-year from $494.0 million in Q1 2025, and up 15.07% quarter-over-quarter from $427.8 million in Q4 2025.
Bicara Therapeutics (BCAX) Assets Average (2024 - 2026) Analysis & Trends
Bicara Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $492.3 million for Q1 2026.
- In Q1 2026, Assets Average changed 0.35% year-over-year to $492.3 million; the TTM figure through Mar 2026 stood at $492.3 million (changed 0.35% YoY), while the FY2025 annual figure was $470.5 million, up 26.48% from the prior year.
- Assets Average for Q1 2026 stood at $492.3 million, up from $427.8 million in the prior quarter.
- The five-year high for Assets Average was $517.1 million in Q4 2024, with the low at $427.8 million in Q4 2025.
- The 3-year median for Assets Average is $479.1 million (2025), against an average of $472.7 million.
- The sharpest annual moves came in 2025 and 2026: Assets Average retreated 17.26% in 2025, then declined 0.35% in 2026.
- Bicara Therapeutics' Assets Average stood at $517.1 million in 2024, then fell by 17.26% to $427.8 million in 2025, then gained by 15.07% to $492.3 million in 2026.
- Business Quant data shows BCAX's Assets Average at $492.3 million in Q1 2026, $427.8 million in Q4 2025, and $439.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 532.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 532.92 Mn |
| Mar 31, 2026 | 492.30 Mn |
| Dec 31, 2025 | 427.84 Mn |
| Sep 30, 2025 | 439.14 Mn |
| Jun 30, 2025 | 465.83 Mn |
| Mar 31, 2025 | 494.04 Mn |
| Dec 31, 2024 | 517.08 Mn |